| Date | Title | | | 02/22/12 | Abiomed to Present at Citi 2012 Global Healthcare Conference| DANVERS, Mass.--(BUSINESS WIRE)--Feb. 22, 2012--
Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Citi 2012
Global Healthcare Conference on Tuesday, February 28, 2012 at 9:30 a.m.
ET. The conference will be held at the Waldorf Astoria Hotel in New York
City.
ABOUT ABIOMED
... |
|  | | 02/03/12 | Abiomed Reports Record Revenue of $32.2 Million and Earnings of $2.9 Million for Third Quarter of Fiscal 2012|
-- Worldwide Impella Revenue Totals $27.7 Million, Up 31% With
Double Digit Sequential and Year over Year Growth in Impella Utilization
DANVERS, Mass.--(BUSINESS WIRE)--Feb. 3, 2012--
Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported third quarter fiscal 2012 revenue
of $32.2 million, up 18% compared to revenue of $27.2 million in the
same period of fiscal 2011 and GAAP net inco... |
| | | 01/31/12 | New Clinical Data for Symphony Presented in Late Breaking Clinical Trials Session at the Society of Thoracic Surgeons 2012 Annual Meeting| FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jan. 31, 2012--
Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that the initial
clinical data from the safety study for Symphony™ was presented by Renzo
Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill
University, during the late-breaking clinical trials session at the
Society of Thoracic Surgeons (STS) 2012 Annual Meeting in... |
| | | 01/26/12 | Abiomed Third Quarter Fiscal 2012 Earnings and Conference Call Notification| DANVERS, Mass.--(BUSINESS WIRE)--Jan. 26, 2012--
Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Friday, February 3, the
Company will release financial results for the third quarter of fiscal
2012. The Company will host a conference call to discuss the results on
Friday, February 3, 2012, at 8:00 a.m. ET. Michael R. Minogue, Chairman,
President and Chief Executive Officer and Robert L. Bowen, Vice
President and Chief Financial Officer, wi... |
| | | 12/12/11 | Abiomed 2011 Investor Day Webcast Replay Available| DANVERS, Mass.--(BUSINESS WIRE)--Dec. 12, 2011--
The webcast from the 2011 investor and analyst day for Abiomed, Inc.
(NASDAQ: ABMD) is available for replay.
To view the 2011 investor and analyst day presentation, please tune into
the archive webcast via direct link at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=95629&eventID=4233864.
The archive webcast and conference call replay will be available until
11:59 p.m... |
| | | 12/09/11 | Abiomed Announces Expanded Heart Recovery Strategy with Multi Year
Growth Initiatives| DANVERS, Mass., Dec 09, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today presented its expanded heart recovery
strategy along with new initiatives that are expected to enhance strong,
multi-year double digit sales and earnings growth. During its annual
investor and analyst day in New York City, Abiomed will discuss the
recently announced PROTECT II clinical and economic developments, ... |
| | | 12/07/11 | Abiomed to Release New Data and Product Updates at Investor & Analyst Day on December 9| DANVERS, Mass.--(BUSINESS WIRE)--Dec. 7, 2011--
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, will release new data and product updates at its
investor and analyst day on Friday, December 9, 2011, from 2:00 to 4:30
p.m. at the New York Palace in New York City.
All interested attendees are encouraged to view the TCTMD webcast on www.abiomed.com
prior to the event, as much of the material discussed... |
| | | 11/28/11 | Catheterization and Cardiovascular Interventions Journal Publishes Results from USpella Registry|
Publication Demonstrates Increase in Ejection Fraction and
Improvement in NYHA Class in Impella Patients, Similar to Recent PROTECT
II Results
DANVERS, Mass.--(BUSINESS WIRE)--Nov. 28, 2011--
Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that results from
prophylactic use of the Impella 2.5 in complex coronary interventions
from the USpella multicenter registry have b... |
| | | 11/21/11 | Abiomed to Present at Piper Jaffray 23rd Annual Healthcare Conference| DANVERS, Mass.--(BUSINESS WIRE)--Nov. 21, 2011--
Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Piper Jaffray
23rd Annual Healthcare Conference on Wednesday, November 30,
2011 at 1:00 p.m. ET. The conference will be held at the New York Palace
Hotel in New York City.
ABOUT AB... |
| | | 11/14/11 | Abiomed Announces Symphony, an Implantable Synchronized Heart Pump Designed for Chronic Heart Failure Patients, at AHA 2011| DANVERS, Mass.--(BUSINESS WIRE)--Nov. 14, 2011--
Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced Symphony™, a new
synchronized minimally invasive implantable cardiac assist device,
designed to treat chronic patients with moderate heart failure by
improving patient hemodynamics, and potentially improving quality of
life. The device is designed with the primary goal of stabilizing the
... |
| | | 11/11/11 | Abiomed Announces Schedule of Events at American Heart Association
2011 Scientific Sessions|
New Product Concept to be Presented During the Sessions
DANVERS, Mass., Nov 11, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that a new product
concept will be presented during the Clinical Science: Special Reports
session at the American Heart Association (AHA) 2011 Scientific Sessions
in Orlando, Florida.
The presentation by Robert Dowling, M.D.,... |
| | | 11/10/11 | New Data Confirms Early Implantation of Impella 2.5 Prior to PCI
Improves Survival in Shock Patients| DANVERS, Mass. & SAN FRANCISCO, Nov 10, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced new results from a
multicenter retrospective study demonstrating that early initiation of
support with Impella(R) 2.5 prior to revascularization improves survival
in emergent patients as compared to those receiving Impella 2.5 support
after percutaneous coronary intervention (... |
| | | 11/10/11 | Abiomed to Present at Lazard Capital Markets 8th
Annual Healthcare Conference| DANVERS, Mass., Nov 10, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Lazard
Capital Markets 8th Annual Healthcare Conference on
Wednesday, November 16, 2011 at 9:30 a.m. ET. The conference will be
held at the Pierre Hotel in New York.
ABOUT ABIOMED
Based in Danvers... |
| | | 11/09/11 | PROTECT II Demonstrates That Patients Undergoing Extensive
Revascularization Benefit the Most from Impella Support|
Extensive Revascularization with Impella Improves Outcomes at 90
Days
DANVERS, Mass. & SAN FRANCISCO, Nov 09, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced the final analysis from
the PROTECT II trial at the annual 2011 Transcatheter Cardiovascular
Therapeutics (TCT) meeting.
PROTECT II is the first study to examine this cohort of complex pati... |
| | | 11/08/11 | Economic Study Demonstrates Cost-Effectiveness of Impella Presented
at TCT 2011| Prophylactic Use of Impella Achieves Cost-Effective Threshold
DANVERS, Mass. & SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced results of an economic study at
the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT)
conference. The economic study demonstrated that Impella significantly
reduced major adverse events at an incremental cost per qual... |
| | | 11/07/11 | ACCF/AHA/SCAI 2011 Guidelines for Percutaneous Coronary Intervention
Incorporates Impella Support| DANVERS, Mass. & SAN FRANCISCO, Nov 07, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced the inclusion of
hemodynamic support with Impella in the 2011 American College of
Cardiology Foundation (ACCF)/American Heart Association (AHA)/ Society
for Coronary Angiography Interventions (SCAI) for percutaneous coronary
intervention (PCI). Released today by the Journal of... |
| | | 11/03/11 | Abiomed Reports Record Revenue of $29.5 Million and Profitability for
Second Quarter of Fiscal 2012, Driven by 40% Impella Growth| -- GAAP Net Income of $0.6 Million
DANVERS, Mass., Nov 03, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported second quarter fiscal 2012 revenue
of $29.5 million, up 26% compared to revenue of $23.4 million in the
same period of fiscal 2011.
Financial and operating highlights during the second quarter of fiscal
2012 include:
Fiscal second quarter ... |
| | | 11/01/11 | Abiomed Announces Investor & Analyst Day in New York City on December
9| Agenda to Include Presentations on Recent PROTECT II Data and New
Product Updates
DANVERS, Mass., Nov 01, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, will host an investor and analyst day on Friday,
December 9, 2011 from 2:00 to 4:30 p.m. at the New York Palace in New
York City.
The agenda will include physician presentations, which will discuss the
new data from PROTECT II and... |
| | | 10/27/11 | Abiomed Second Quarter Fiscal 2012 Earnings and Conference Call
Notification| DANVERS, Mass., Oct 27, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Thursday, November 3,
the Company will release financial results for the second quarter of
fiscal 2012. The Company will host a conference call to discuss the
results on Thursday, November 3, 2011, at 8:00 a.m. ET. Michael R.
Minogue, Chairman, President and Chief Executive Officer and Robert L.
Bowen, Vice President and Chief Financial Officer, will... |
| | | 10/26/11 | Abiomed to Release New Protect II Data and Economic Study Results at
TCT 2011; Over 20 Impella Presentations Included in Show Schedule| - Abiomed Sponsoring Three-Part Breakfast Series
DANVERS, Mass., Oct 26, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced its schedule of events
at the Cardiovascular Research Foundation's (CRF) annual Transcatheter
Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from
November 7-11, at the Moscone Center in San Francisco.
See below for the full schedul... |
| | | 09/19/11 | Abiomed Announces First Patient Enrolled In MINI-AMI Study| CRISP-AMI Trial Demonstrates Large Infarcts in Stable STEMI
Patient Population
DANVERS, Mass., Sep 19, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced the first patient enrolled in
MINI-AMI, an FDA prospective, randomized, controlled multi-center study
to assess the role of 24-hours of direct unloading of the left ventricle
with Impella(R) 2.5 support to reduce infarct s... |
| | | 09/16/11 | Abiomed to Present at Lazard Capital Markets Circulatory Assist
Device Day| DANVERS, Mass., Sep 16, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Lazard
Capital Markets 3rd Annual Circulatory Assist Device Day on
Thursday, September 22, 2011 at 10:55 a.m. ET. The conference will be
held at the Langham Hotel in Boston, MA.
ABOUT ABIOMED
Base... |
| | | 09/06/11 | Abiomed to Present at Morgan Stanley 2011 Global Healthcare Unplugged
Conference| DANVERS, Mass., Sep 06, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that Michael R. Minogue,
Chairman, President and Chief Executive Officer, will present at the
Morgan Stanley 2011 Global Healthcare Conference on Wednesday, September
14, 2011 at 9:45 a.m. ET. The conference will be held at the Grand Hyatt
Hotel in New York, NY.
ABOUT ABIOMED
Based in Danv... |
| | | 09/01/11 | Abiomed to Present at the Baird 2011 Healthcare Conference| DANVERS, Mass., Sep 01, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that Michael R. Minogue,
Chairman, President and Chief Executive Officer, Abiomed, will present
at the Baird 2011 Healthcare Conference on Wednesday, September 7, 2011
at 9:30 a.m. ET. The conference will be held at the New York Palace in
New York, NY.
ABOUT ABIOMED
Based in Danvers, Massa... |
| | | 08/11/11 | Abiomed To Present At The Wedbush 2011 Life Sciences: Management Access Conference| DANVERS, Mass., August 11, 2011 -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert Bowen, Chief Financial Officer and Vice President, will present at the Wedbush 2011 Life Sciences: Management Access Conference on Tuesday, August 16, 2011 at 11:10 a.m. ET. The conference will be held at Le Parker Meridien Hotel in New York, NY.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medica... |
| | | 08/04/11 | Abiomed Reports Revenue of $27.4 Million, up 25% over Prior Year, for
First Quarter of Fiscal 2012| -- Impella Revenues Grow 33% to $22.2 Million
DANVERS, Mass., Aug 04, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported first quarter fiscal 2012 revenue
of $27.4 million, up 25% compared to revenue of $22.0 million in the
same period of fiscal 2011.
Financial and operating highlights during the first quarter of fiscal
2012 include:
Fiscal first ... |
| | | 07/28/11 | Abiomed First Quarter Fiscal 2012 Earnings and Conference Call
Notification| DANVERS, Mass., Jul 28, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Thursday, August 4, the
Company will release financial results for the first quarter of fiscal
2012.
The Company will host a conference call to discuss the results on
Thursday, August 4, 2011, at 8:00 a.m. ET. Michael R. Minogue, Chairman,
President and Chief Executive Officer and Robert L. Bowen, Vice
President and Chief Financial Officer, will... |
| | | 06/02/11 | Abiomed to Present at Jefferies 2011 Global Healthcare Conference| DANVERS, Mass., Jun 02, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Jefferies
2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 4:30
p.m. ET. The conference will be held at the Mandarin Oriental in New
York City.
ABOUT ABIOMED
Based in Danvers, Massachusetts... |
| | | 06/01/11 | Abiomed Announces Appointment of Paul G. Thomas to Board of Directors| DANVERS, Mass., Jun 01, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced the appointment of Paul G. Thomas
to the Company's Board of Directors.
Currently, Mr. Thomas is Chief Executive Officer and Founder of Roka
Bioscience, a company focused on the development and commercialization
of molecular assays and is a Director of Orthovita, Inc. (NASDAQ: VITA).
Mr. Tho... |
| | | 05/18/11 | Abiomed Reports Record Fiscal Fourth Quarter Revenue of $28.5
Million, up 24% over Prior Year| - $101.2 Million in Total Revenue With Gross Margins of 78% for Full
Fiscal Year
DANVERS, Mass., May 18, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported fourth quarter fiscal 2011 revenue
of $28.5 million, up 24% compared to revenue of $23.0 million in the
same period of fiscal 2010. Total revenue for the full fiscal year was
$101.2 million, up 18% compared to rev... |
| | | 05/11/11 | Abiomed Announces PROTECT II Study Data Will Be Presented at EuroPCR
2011 in Late-Breaking Clinical Trial Session| - PROTECT II Presentation, Including Latest Data on 90-Day Results,
Scheduled for Friday, May 20, Between 9:10 a.m. - 12:10 p.m. (CEST)
DANVERS, Mass., May 11, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that data from the
PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director
of Interventional Services at NewYork-Presbyterian Hospital/Columbia
... |
| | | 05/10/11 | Abiomed Fourth Quarter and Full Year Fiscal 2011 Earnings and
Conference Call Notification| DANVERS, Mass., May 10, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Wednesday, May 18, 2011,
the Company will release financial results for the fourth quarter and
full year of fiscal 2011. The Company will host a conference call to
discuss the results on Wednesday, May 18, 2011, at 8:00 a.m. ET. Michael
R. Minogue, Chairman, President and Chief Executive Officer and Robert
L. Bowen, Vice President and Chief Financial... |
| | | 05/09/11 | Abiomed to Present at Bank of America Merrill Lynch 2011 Healthcare
Conference| DANVERS, Mass., May 09, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will present at the Bank of
America Merrill Lynch 2011 Healthcare Conference on Thursday, May 12,
2011 at 11:10 a.m. PT/ 2:10 p.m. ET. The conference will be held at the
Encore at Wynn Las Vegas in Las Vegas, NV.
ABOUT ABIOME... |
| | | 04/18/11 | New Data from the Protect II Study to Be Presented in Late Breaking
Clinical Trials Session at Society for Cardiovascular Angiography
Interventions 2011 Scientific Sessions| - PROTECT II Presentation, Including New Data and 90 Day Results,
Scheduled for Friday, May 6 at 12 p.m. ET
DANVERS, Mass., Apr 18, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that new data from the
PROTECT II study will be presented by William O'Neill, M.D., executive
dean for clinical affairs at the University of Miami Miller School of
Medicine, and principa... |
| | | 04/03/11 | Abiomed Announces Schedule of Events at American College of
Cardiology 2011 Scientific Conference| DANVERS, Mass., Apr 03, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced the schedule of events at American
College of Cardiology (ACC) 2011 Scientific Conference in New Orleans.
Schedule of Abiomed Events at ACC 2011
Impella presentations at ACC 2011 will take place during the following
dates and times:
Sunday, April 3
12:30 p.m. CT
Room 257
Ernest N. Morial Convention
... |
| | | 03/24/11 | Abiomed to Host PROTECT II Investor Meeting at ACC 2011| - Presentation Will Be Webcast Live and Available on Abiomed
Website
DANVERS, Mass., Mar 24, 2011 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, will host a PROTECT II investor and analyst
meeting and webcast from ACC 2011 on Monday, April 4, from 8:00 - 9:00
a.m. ET.
The presentation will include the PROTECT II data, which will be
presented by William O'Neill, M.D., University of Miam... |
| | | 02/22/11 | PROTECT II Study Results Accepted for Presentation at 2011 ACC Show
During Late Breaking Sessions| - Presentation Updated to Include Data From Approximately All 430
Patients Enrolled in Study
DANVERS, Mass., Feb 22, 2011 (BUSINESS WIRE) --Abiomed
Inc. (NASDAQ: ABMD), a leading provider of breakthrough
heart support technologies, today announced that the PROTECT II
results have been accepted to be presented by William O'Neill, M.D.,
University of Miami, during the late-breaking clinical trials session at
the American College of Cardiology (ACC... |
| | | 02/04/11 | Abiomed to Ring NASDAQ Closing Bell; Signifying Start of Heart Month
and Celebrating a Successful Quarter|
Female Heart Recovery Patients Will Join Abiomed CEO for Ceremony
NASDAQ Ceremony Follows Abiomed Third Quarter Earnings
Announcement
DANVERS, Mass., Feb 04, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced that Michael R. Minogue, Chairman,
President and Chief Executive Officer, will ring the Closing Bell for
The NASDAQ Stock Market today at 4 ... |
| | | 02/03/11 | Abiomed Announces Survey Results and Launches National Heart Recovery
Awareness Campaign|
Study Indicates Strong Preference Among Adults to "Keep Their Own
Hearts"
Awareness Campaign Focuses on Acute Heart Failure Education for
Women
DANVERS, Mass., Feb 03, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) today announced that it will kick off American
Heart month by launching a national campaign to raise awareness for heart
recovery. This campaign will focus on educating women since they
have a lower s... |
| | | 02/03/11 | Abiomed Increases Revenues by 19% to $27.2 Million and Achieves
Non-GAAP Profitability While Generating $5 Million in Cash for Third
Quarter of Fiscal 2011| - Record U.S. Utilization of 752 Patients, Up 77% Over Prior Year
DANVERS, Mass., Feb 03, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported third quarter fiscal 2011 revenue
of $27.2 million, up 19% compared to the same period of fiscal 2010.
Worldwide Impella revenue totaled $21.1 million, up 33% compared to
revenue of $15.9 million during the same period of the prior year.
... |
| | | 01/26/11 | Abiomed Third Quarter Fiscal 2011 Earnings and Conference Call
Notification| DANVERS, Mass., Jan 26, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Thursday, February 3,
2011, the Company will release financial results for the third quarter
of fiscal 2011. The Company will host a conference call to discuss the
results on Thursday, February 3, 2011, at 8:00 a.m. ET. Michael R.
Minogue, Chairman, President and Chief Executive Officer and Robert L.
Bowen, Vice President and Chief Financial Officer,... |
| | | 01/06/11 | Abiomed to Present at JP Morgan 29th Annual
Healthcare Conference in San Francisco| DANVERS, Mass., Jan 06, 2011 (BUSINESS WIRE) --Abiomed,
Inc. (NASDAQ: ABMD) today announced that Michael R. Minogue,
Chairman, President and Chief Executive Officer, will present at the 29th
Annual JP Morgan Healthcare Conference on Thursday, January 13, 2010 at
10:30 a.m. PT/ 1:30 p.m. ET. The conference will be held at the Westin
St. Francis from January 10 - 13, in San Francisco, California.
A live audio webcast of the presentation will be availabl... |
| |
|
